{"transactions":[{"id":737547,"issuer":{"id":8036,"kind":"organization","name":"BullFrog AI Holdings, Inc.","symbol":"BFRG"},"owners":[{"id":38083,"kind":"person","name":"Hanson Jason David","position":1,"cik":"0001368586","reported_name":"Hanson Jason David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2026-06-15T21:29:56.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The options were issued as a grant under the Plan, based on the market price on the date of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options issued under BullFrog AI Holdings, Inc.'s (the \"Company\") 2022 Equity Compensation Plan, as amended from time to time (the \"Plan\"), which vest on June 11, 2027. Lapse of forfeiture restrictions will accelerate upon a change in control of the Company (as defined in the Plan) or a significant financing, which may, or may not, constitute a change in control."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The stock options expire on June 12, 2036."}],"balance_after":15000,"derivative":{"exercise_price":0.6281,"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001493152-26-028744","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368586/000149315226028744/ownership.xml","form_type":"4"}},{"id":1031111,"issuer":{"id":8036,"kind":"organization","name":"BullFrog AI Holdings, Inc.","symbol":"BFRG"},"owners":[{"id":38083,"kind":"person","name":"Hanson Jason David","position":1,"cik":"0001368586","reported_name":"Hanson Jason David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2025-09-30T00:16:41.000Z","date":"2025-09-25","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The options were issued as a grant under the Plan, based on the market price on the date of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options issued under Bullfrog AI Holdings, Inc.'s (the \"Company\") 2022 Equity Compensation Plan, as amended from time to time (the \"Plan\"), vesting on the earlier of September 25, 2026 and the date of the Company's annual meeting for fiscal year 2026. Lapse of forfeiture restrictions will accelerate upon a change in control of the Company (as defined in the Plan) or a significant financing which may, or may not, constitute a change in control."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The stock options expire on September 25, 2035."}],"balance_after":15000,"derivative":{"exercise_price":1.43,"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001493152-25-016101","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368586/000149315225016101/ownership.xml","form_type":"4"}},{"id":1055491,"issuer":{"id":8036,"kind":"organization","name":"BullFrog AI Holdings, Inc.","symbol":"BFRG"},"owners":[{"id":38083,"kind":"person","name":"Hanson Jason David","position":1,"cik":"0001368586","reported_name":"Hanson Jason David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-26T20:05:42.000Z","date":"2025-08-22","kind":"grant","planned":false,"acquired":true,"shares":2813,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents 2,813 shares of Common Stock issued as an equity grant under the Plan, fully vested upon grant."}],"balance_after":8523,"source":{"system":"sec-edgar","filing":"0001641172-25-025527","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1368586/000164117225025527/ownership.xml","form_type":"4"}},{"id":1055490,"issuer":{"id":8036,"kind":"organization","name":"BullFrog AI Holdings, Inc.","symbol":"BFRG"},"owners":[{"id":38083,"kind":"person","name":"Hanson Jason David","position":1,"cik":"0001368586","reported_name":"Hanson Jason David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-26T20:05:42.000Z","date":"2025-08-22","kind":"grant","planned":false,"acquired":true,"shares":5710,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") issued under the Company's 2022 Equity Compensation Plan (the \"Plan\"), vesting 50% on September 1, 2026, and the remaining 50% on September 1, 2027. Lapse of forfeiture restrictions will accelerate upon a change in control of the Company (as defined in the Plan) or a significant financing which may, or may not, constitute a change in control. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer."}],"balance_after":5710,"source":{"system":"sec-edgar","filing":"0001641172-25-025527","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368586/000164117225025527/ownership.xml","form_type":"4"}},{"id":1271249,"issuer":{"id":8036,"kind":"organization","name":"BullFrog AI Holdings, Inc.","symbol":"BFRG"},"owners":[{"id":38083,"kind":"person","name":"Hanson Jason David","position":1,"cik":"0001368586","reported_name":"Hanson Jason David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2025-02-12T14:00:14.000Z","date":"2024-09-26","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F1","text":"The options vest on September 26, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The options were issued as a grant under the Company's equity incentive plan based on the market price on the date of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest on September 26, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The options expire on September 26, 2034."}],"balance_after":15000,"derivative":{"exercise_price":2.96,"underlying":"Common stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001493152-25-006048","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368586/000149315225006048/ownership.xml","form_type":"5"}},{"id":1751102,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":38083,"kind":"person","name":"Hanson Jason David","position":1,"cik":"0001368586","reported_name":"Hanson Jason David","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-02T20:09:58.000Z","date":"2023-07-07","kind":"grant","planned":false,"acquired":true,"shares":512826,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 31, 2023 (the \"Closing Date\"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the \"Business Combination Agreement\"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation (\"FEAC\"), enGene Inc., a corporation incorporated under the laws of Canada (\"enGene\"), and enGene Holdings Inc. (the \"Issuer\" or \"New enGene\"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene.  The transactions contemplated by the Business Combination Agreement are referred to herein as the \"Business Combination\"."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer (\"Common Shares\") for each share of enGene held by them immediately prior to the Closing Date.  Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"7. This option was granted on July 7, 2023 on the condition it is not exercisable unless and until (i) the Business Combination Agreement has been completed and (ii) an effective registration statement for the New enGene shares underlying such granted options has been filed. This option was received in the Business Combination in exchange for an option to purchase 2,841,461 common shares of enGene.  This option is fully vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"7. This option was granted on July 7, 2023 on the condition it is not exercisable unless and until (i) the Business Combination Agreement has been completed and (ii) an effective registration statement for the New enGene shares underlying such granted options has been filed. This option was received in the Business Combination in exchange for an option to purchase 2,841,461 common shares of enGene.  This option is fully vested."}],"balance_after":512826,"derivative":{"exercise_price":4.25,"expiration_date":"2033-07-07","underlying":"Common Shares","underlying_shares":512826},"source":{"system":"sec-edgar","filing":"0000929638-23-002989","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1368586/000092963823002989/form4.xml","form_type":"4"}},{"id":1751101,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":38083,"kind":"person","name":"Hanson Jason David","position":1,"cik":"0001368586","reported_name":"Hanson Jason David","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-02T20:09:58.000Z","date":"2021-08-20","kind":"grant","planned":false,"acquired":true,"shares":10906,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 31, 2023 (the \"Closing Date\"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the \"Business Combination Agreement\"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation (\"FEAC\"), enGene Inc., a corporation incorporated under the laws of Canada (\"enGene\"), and enGene Holdings Inc. (the \"Issuer\" or \"New enGene\"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene.  The transactions contemplated by the Business Combination Agreement are referred to herein as the \"Business Combination\"."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer (\"Common Shares\") for each share of enGene held by them immediately prior to the Closing Date.  Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"6. This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 60,429 common shares of enGene."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"6. This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 60,429 common shares of enGene."}],"balance_after":10906,"derivative":{"exercise_price":0.88,"expiration_date":"2031-08-20","underlying":"Common Shares","underlying_shares":10906},"source":{"system":"sec-edgar","filing":"0000929638-23-002989","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1368586/000092963823002989/form4.xml","form_type":"4"}},{"id":1751100,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":38083,"kind":"person","name":"Hanson Jason David","position":1,"cik":"0001368586","reported_name":"Hanson Jason David","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-02T20:09:58.000Z","date":"2021-08-20","kind":"grant","planned":false,"acquired":true,"shares":524544,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 31, 2023 (the \"Closing Date\"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the \"Business Combination Agreement\"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation (\"FEAC\"), enGene Inc., a corporation incorporated under the laws of Canada (\"enGene\"), and enGene Holdings Inc. (the \"Issuer\" or \"New enGene\"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene.  The transactions contemplated by the Business Combination Agreement are referred to herein as the \"Business Combination\"."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer (\"Common Shares\") for each share of enGene held by them immediately prior to the Closing Date.  Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 2,906,386 common shares of enGene."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 2,906,386 common shares of enGene."}],"balance_after":524544,"derivative":{"exercise_price":0.88,"expiration_date":"2031-08-20","underlying":"Common Shares","underlying_shares":524544},"source":{"system":"sec-edgar","filing":"0000929638-23-002989","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1368586/000092963823002989/form4.xml","form_type":"4"}},{"id":1751099,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":38083,"kind":"person","name":"Hanson Jason David","position":1,"cik":"0001368586","reported_name":"Hanson Jason David","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-02T20:09:58.000Z","date":"2019-07-30","kind":"grant","planned":false,"acquired":true,"shares":30939,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 31, 2023 (the \"Closing Date\"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the \"Business Combination Agreement\"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation (\"FEAC\"), enGene Inc., a corporation incorporated under the laws of Canada (\"enGene\"), and enGene Holdings Inc. (the \"Issuer\" or \"New enGene\"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene.  The transactions contemplated by the Business Combination Agreement are referred to herein as the \"Business Combination\"."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer (\"Common Shares\") for each share of enGene held by them immediately prior to the Closing Date.  Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 171,429 common shares of enGene."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 171,429 common shares of enGene."}],"balance_after":30939,"derivative":{"exercise_price":0.88,"expiration_date":"2029-07-30","underlying":"Common Shares","underlying_shares":30939},"source":{"system":"sec-edgar","filing":"0000929638-23-002989","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1368586/000092963823002989/form4.xml","form_type":"4"}},{"id":1751098,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":38083,"kind":"person","name":"Hanson Jason David","position":1,"cik":"0001368586","reported_name":"Hanson Jason David","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-02T20:09:58.000Z","date":"2018-07-09","kind":"grant","planned":false,"acquired":true,"shares":137051,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 31, 2023 (the \"Closing Date\"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the \"Business Combination Agreement\"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation (\"FEAC\"), enGene Inc., a corporation incorporated under the laws of Canada (\"enGene\"), and enGene Holdings Inc. (the \"Issuer\" or \"New enGene\"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene.  The transactions contemplated by the Business Combination Agreement are referred to herein as the \"Business Combination\"."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer (\"Common Shares\") for each share of enGene held by them immediately prior to the Closing Date.  Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 759,374 common shares of enGene."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 759,374 common shares of enGene."}],"balance_after":137051,"derivative":{"exercise_price":0.88,"expiration_date":"2028-07-09","underlying":"Common Shares","underlying_shares":137051},"source":{"system":"sec-edgar","filing":"0000929638-23-002989","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368586/000092963823002989/form4.xml","form_type":"4"}},{"id":1899274,"issuer":{"id":8036,"kind":"organization","name":"BullFrog AI Holdings, Inc.","symbol":"BFRG"},"owners":[{"id":38083,"kind":"person","name":"Hanson Jason David","position":1,"cik":"0001368586","reported_name":"Hanson Jason David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (Right to buy)","published_at":"2023-05-09T21:22:07.000Z","date":"2023-04-16","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F1","text":"The options vest as follows: 8,888 options were deemed immediately vested and, each month thereafter 864 shares vest per month."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest as follows: 8,888 options were deemed immediately vested and, each month thereafter 864 shares vest per month."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The option expires on April 16, 2033."}],"balance_after":40000,"derivative":{"exercise_price":6.82,"underlying":"Common stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001493152-23-015988","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368586/000149315223015988/ownership.xml","form_type":"4"}}]}